Donoghue Forlines LLC Exelixis, Inc. Transaction History

Donoghue Forlines LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$18.17 - $20.48 $223,272 - $251,658	12,288 New	12,288 $234,000
Q3 2022 Nov 07, 2022	SELL	$15.68 - $22.27 $171,162 - $243,099	-10,916 Reduced 51.68%	10,208 $160,000
Q2 2022 Aug 08, 2022	BUY	$17.44 - $23.16 $368,402 - $489,231	21,124 New	21,124 $440,000
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $590,648 - $725,579	-28,770 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$18.39 - $24.8 $529,080 - $713,496	28,770 New	28,770 $577,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Donoghue Forlines LLC, based on Form 13F filings with the SEC.

Stay updated on Donoghue Forlines LLC with notifications on news.